{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:41Z","timestamp":1787021081703,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treating refractory status epilepticus (RSE) remains a challenge. Thiamylal can be used as a second- or third-line treatment; however, its potential to induce cytochrome P450 (CYP) activity may reduce the concentration of antiepileptic drugs (AEDs) administered prior to thiamylal. This report details a case of RSE patient treated with thiamylal, with monitored concentrations of thiamylal and other AEDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 72-year-old healthy man developed RSE. Despite the administration of various AEDs, his seizures were not resolved. Thiamylal was then administered at an initial bolus dose of 2.1\u00a0mg\/kg, followed by a continuous infusion of 4.2\u20135.2\u00a0mg\/kg\/h. The initial thiamylal concentration was observed at 7.8\u00a0\u03bcg\/mL, increasing to 35.2\u00a0\u03bcg\/mL before decreasing after dose reduction and cessation. Concurrently, the concentration of concomitant carbamazepine decreased from 5.59\u00a0\u03bcg\/mL to 2.1\u00a0\u03bcg\/mL and recovered as thiamylal concentration decreased. Lesser impacts were noted for other AEDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case report underscored the efficacy of thiamylal in treating RSE. However, it also highlighted the need for clinicians to closely monitor the concentrations of concurrent AEDs, especially carbamazepine, during thiamylal therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-024-00362-w","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:01:47Z","timestamp":1720771307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thiamylal serum concentration for refractory convulsive status epilepticus while associated decreased concentrations of concomitant antiepileptics: a case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-1896","authenticated-orcid":false,"given":"Kazutaka","family":"Oda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Katanoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Arakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Katsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Jono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"2","key":"362_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/epi4.12394","volume":"5","author":"DR Kafle","year":"2020","unstructured":"Kafle DR, Avinash AJ, Shrestha A. Predictors of outcome in refractory generalized convulsive status epilepticus. Epilepsia Open. 2020;5(2):248\u201354.","journal-title":"Epilepsia Open"},{"issue":"Pt B","key":"362_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.07.014","volume":"101","author":"AM Kantanen","year":"2019","unstructured":"Kantanen AM, Sairanen J, K\u00e4lvi\u00e4inen R. Incidence of the different stages of status epilepticus in Eastern Finland: a population-based study. Epilepsy Behav. 2019;101(Pt B): 106413.","journal-title":"Epilepsy Behav"},{"issue":"22","key":"362_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103\u201313.","journal-title":"N Engl J Med"},{"key":"362_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-0404.2007.00811.x","volume":"186","author":"K Sugai","year":"2007","unstructured":"Sugai K. Treatment of convulsive status epilepticus in infants and young children in Japan. Acta Neurol Scand Suppl. 2007;186:62\u201370.","journal-title":"Acta Neurol Scand Suppl"},{"key":"362_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.seizure.2020.03.012","volume":"80","author":"Y Ishida","year":"2020","unstructured":"Ishida Y, Nishiyama M, Yamaguchi H, Tomioka K, Tanaka T, Takeda H, et al. Thiamylal anaesthetic therapy for febrile refractory status epilepticus in children. Seizure. 2020;80:12\u20137.","journal-title":"Seizure"},{"issue":"9","key":"362_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.5692\/clinicalneurol.54.715","volume":"54","author":"D Yamamoto","year":"2014","unstructured":"Yamamoto D, Uchiyama T, Bunai T, Sato K, Shimizu T, Tanaka K, et al. Acute encephalitis with refractory partial status epilepticus treated with early immunotherapies including plasma exchange: a case report. Rinsho Shinkeigaku. 2014;54(9):715\u201320.","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"362_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1607-551X(09)70383-3","volume":"23","author":"CJ Tsai","year":"2007","unstructured":"Tsai CJ, Wang HM, Lu IC, Tai CF, Wang LF, Soo LY, et al. Seizure after local anesthesia for nasopharyngeal angiofibroma. Kaohsiung J Med Sci. 2007;23(2):97\u2013100.","journal-title":"Kaohsiung J Med Sci"},{"issue":"6","key":"362_CR8","first-page":"691","volume":"53","author":"H Fukushima","year":"2004","unstructured":"Fukushima H, Ishiyama T, Oguchi T, Masui K, Matsukawa T, Kumazawa T. Refractory generalized convulsions in a patient undergoing brain tumor resection during propofol anesthesia. Masui. 2004;53(6):691\u20132.","journal-title":"Masui"},{"issue":"4","key":"362_CR9","first-page":"125","volume":"39","author":"Y Taira","year":"1990","unstructured":"Taira Y, Fujii K, Kikuchi H, Yuge O, Morio M. Effects of in vivo pretreatment with various barbiturates on anaerobic halothane metabolism in rat liver microsomes. Hiroshima J Med Sci. 1990;39(4):125\u201330.","journal-title":"Hiroshima J Med Sci"},{"issue":"2","key":"362_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1528-1157.2000.tb00144.x","volume":"41","author":"G Jannuzzi","year":"2000","unstructured":"Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia. 2000;41(2):222\u201330.","journal-title":"Epilepsia"},{"issue":"2","key":"362_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.719","volume":"9","author":"Y Yamakawa","year":"2021","unstructured":"Yamakawa Y, Morioka M, Negoto T, Orito K, Yoshitomi M, Nakamura Y, et al. A novel step-down infusion method of barbiturate therapy: its safety and effectiveness for intracranial pressure control. Pharmacol Res Perspect. 2021;9(2): e00719.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"362_CR12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","volume":"42","author":"HM Neels","year":"2004","unstructured":"Neels HM, Sierens AC, Naelaerts K, Scharp\u00e9 SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42(11):1228\u201355.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"362_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.102.033837","volume":"302","author":"JL Raucy","year":"2002","unstructured":"Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther. 2002;302(2):475\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"362_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","volume":"56","author":"PN Patsalos","year":"2015","unstructured":"Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12\u201327.","journal-title":"Epilepsia"},{"issue":"6","key":"362_CR15","first-page":"593","volume":"30","author":"T Saito","year":"2002","unstructured":"Saito T, Kurashima A, Oda T, Aoki S, Endo H, Nashimoto T, et al. Quantitative analysis of plasma concentration of barbiturate for diagnosis of brain death. No Shinkei Geka. 2002;30(6):593\u20139.","journal-title":"No Shinkei Geka"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00362-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:03:12Z","timestamp":1720771392000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00362-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00362-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Kumamoto University Hospital waived the need for ethical approval for this study. This study was not classified as a clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided informed consent for the publication of all events occurring during the comprehensive medical course.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}